AAAAI2023 Archive - ClinCompetence Cologne GmbH

Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients – from first-in-human to clinical validation in 3 studies

16. March 2023 | Publication

Affiliations Ralph Mösges, PhD, MD FAAAAI Esther Raskopf, PhD Silke Allekotte, PhD Mandy Cuevas, MD Enrique Fernandez-Caldas, PhD José. L. Subiza, MD, PhD Miguel Casanovas, MD, PhD Rationale The aim of a drug development program for allergen immunotherapies is to get...

Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe and well tolerated – data from 3 sequential trials

16. March 2023 | Publication

Affiliations Silke Allekotte, PhD Esther Raskopf, PhD Laura England Christian Neuhof Hacer Sahin, PhD Lea Radtke, PhD Christoph Zeyen Lea Decker Elena Xenofontos Friederike Hüffmeier Mandy Cuevas, MD Miguel Casanovas, MD, PhD José. L. Subiza, MD, PhD Enrique...

Mannan-conjugated birch pollen allergoids reduce the combined symptom and medication score in birch pollen allergic patients already in the first treatment year and further decreases with prolonged treatment duration

https://clincompetence.de/wp-content/uploads/2023/03/T502_Poster_CSMS_AAAAI_2023.pdf

Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids shows long-term effects already after 2 years of treatment by inducing a significant immune response in birch pollen allergic patients

16. March 2023 | Publication

Affiliations Esther Raskopf, PhD Laura England Hacer Sahin, PhD Lea Radtke, PhD Christoph Zeyen Lea Decker Friederike Hüffmeier Elena Xenofontos Mandy Cuevas, MD Miguel Casanovas, MD, PhD Enrique Fernandez-Caldas, PhD José. L. Subiza, MD, PhD Silke Allekotte, PhD...

Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients – from first-in-human to clinical validation in 3 studies

Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe and well tolerated – data from 3 sequential trials

Mannan-conjugated birch pollen allergoids reduce the combined symptom and medication score in birch pollen allergic patients already in the first treatment year and further decreases with prolonged treatment duration

Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids shows long-term effects already after 2 years of treatment by inducing a significant immune response in birch pollen allergic patients

Contact information

Postal address

Unsere Kontaktdaten

Postanschrift